The purpose of this review article is to report the latest information on MIF, its role in primary CNS tumors—with an emphasis on the most common malignant type, glioblastoma, but also including craniopharyngioma, medulloblastoma, meningioma, pituitary adenoma, and vestibular schwannoma—available MIF-directed treatments, and potential future therapies. The gene discussed is MIF; the disease is craniopharyngioma.